Antoni Ribas

Antoni Ribas led the KEYNOTE-006 phase III trial comparing pembrolizumab versus ipilimumab in advanced melanoma that established pembrolizumab as superior to ipilimumab and as a new first-line standard of care for advanced melanoma. His research on PD-1 pathway blockade contributed foundational clinical evidence for pembrolizumab efficacy across multiple cancer types and helped establish PD-1 inhibitors as a major new therapeutic class. He has made major contributions to adoptive T cell therapy, melanoma immunology, and understanding mechanisms of primary and acquired resistance to checkpoint inhibitors through tumor genomics and immune profiling studies. His clinical and translational work has been central to the cancer immunotherapy revolution.